18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial - The Lancet

Por um escritor misterioso

Descrição

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI - ScienceDirect
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Cancers, Free Full-Text
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
PDF) Impact of Fluciclovine (18F) Positron Emission Tomography on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Cancers, Free Full-Text
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Clinical practice in prostate PET imaging - Sean J. Huls, Brian Burkett, Eric Ehman, Val J. Lowe, Rathan M. Subramaniam, A. Tuba Kendi, 2023
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Advances in Prostate Cancer Imaging
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Cancers, Free Full-Text
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
PET Radiotracer Boosts Survival in Postprostatectomy Salvage Radiotherapy
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide  postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a  single centre, open-label, phase 2/3 randomised controlled trial - The  Lancet
Frontiers Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada
de por adulto (o preço varia de acordo com o tamanho do grupo)